Carcinome neuroendocrine primitif du sein

Trabelsi, Amel; Abdelkrim, Soumaya Ben; Stita, Wided; Gharbi, Olfa; Jaïdane, L.; Hmissa, Sihem; Korbi, S.

doi:10.1016/s1776-9817(08)77197-9

Cited by 5 publications

(26 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Focal neuroendocrine differentiation is reported in approximately 2-5% of breast cancers [12]. Sapino et al proposed a classification of breast endocrine tumors into five types: the cohesive solid variant; the alveolar form; the small cell form; the papillary solid variant; and mucinous carcinoma [13,14]. These last two forms are characterized by the production of mucus and the frequent association with an in situ component with endocrine differentiation [14].…”

Section: Discussionmentioning

confidence: 99%

“…There is no specific clinical or radiological sign to diagnose a neuroendocrine carcinoma; a histological examination is the only way to confirm the diagnosis of this tumor [8,9]. On macroscopic examination, primary neuroendocrine carcinomas of the breast are round or multilobulated, yellowish-colored, and have a firm consistency, or, rarely, they are gelatinous if associated with a mucinous component [4,13]. At histological examination, a diagnosis of the neuroendocrine differentiation of these tumors can be suspected morphologically and should always be confirmed after immunohistochemical analysis by showing positive staining with neuroendocrine markers by at least 50% of the tumor cells.…”

Section: Discussionmentioning

confidence: 99%

“…The evolution of neuroendocrine tumors of the breast is slow. Their prognosis depends mainly on the histological grade and the anatomoclinical stage [13,20,21]. These tumors are histologically graded as their counterparts in other sites [4,13].…”

Section: Discussionmentioning

confidence: 99%

“…Their prognosis depends mainly on the histological grade and the anatomoclinical stage [13,20,21]. These tumors are histologically graded as their counterparts in other sites [4,13]. Thus, the solid variant of neuroendocrine carcinomas and atypical carcinoids have better prognoses than small cell neuroendocrine carcinomas and undifferentiated large cell carcinomas.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Primary neuroendocrine tumors of the breast: two case reports and review of the literature

Hejjane¹,

Oualla²,

Bouchbika³

et al. 2020

J Med Case Reports

View full text Add to dashboard Cite

Background: Neuroendocrine carcinomas mainly affect the bronchopulmonary and the gastrointestinal systems. Breast localizations are very rare. They represent less than 0.1% of all breast cancers. A definitive diagnosis relies on histological and immunohistochemical examinations. Case presentation: Case 1 We report a case of primary neuroendocrine carcinoma of the breast in a 71-year-old Arabic woman who presented with a 3 cm palpable and mobile tumor of the right breast. Clinical and radiological assessment excluded any other primary tumor. Radical mastectomy and axillary lymph node resection were performed. A histopathological examination disclosed the diagnosis of primary breast neuroendocrine tumors, with negative surgical margins and lymph nodes (18 N-/18 N). The tumor cells were positive for neuroendocrine markers, a weak Ki-67 proliferation index and negative Her2/neu. Our patient received adjuvant hormonal treatment with antiaromatase for 21 months. She is on regular follow-up, and she remains free of disease to date. Case 2 A 48-year-old Arabic woman consulted for a right breast nodule. She underwent lumpectomy with right axillary lymphadenectomy. The diagnosis was breast neuroendocrine tumor. Systemic treatment was proposed, but she was lost to follow-up. She consulted 1 year later for a mass in the same breast. A histological and immunohistochemical examination of a mammary biopsy was consistent with a recurrence of the previous neuroendocrine tumor. A radiological assessment showed a large mass in her right breast, ipsilateral axillary lymphadenopathies, and hepatic and pulmonary metastases. She received first-line metastatic chemotherapy, with good clinical and radiological improvement. She refused the mastectomy and was given hormone therapy. One year later, the tumor expanded clinically and radiologically, and she underwent second-line metastatic chemotherapy, with good clinical progress and radiological stability, and she then underwent maintenance hormonal therapy. Conclusion: Due to the rarity of primary breast neuroendocrine tumors, no standard therapy exists and the prognosis remains difficult to determine. Studies, including larger series, are needed in order to understand the biological behavior of these tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Primary neuroendocrine tumors of the breast: two case reports and review of the literature

Hejjane¹,

Oualla²,

Bouchbika³

et al. 2020

J Med Case Reports

View full text Add to dashboard Cite

show abstract

“…Les carcinomes neuroendocrines primitifs du sein sont rares et représentent 2 à 5% des cancers mammaires [1–3]. Les formes primitives sont encore plus rares.…”

Section: Discussionunclassified

Tumeur neuroendocrine mammaire primitive: à propos d’un cas rare

Laabadi¹,

Jayi²,

A³

et al. 2013

Pan Afr Med J

View full text Add to dashboard Cite

Les carcinomes neuroendocrine primitifs du sein sont des tumeurs rares et représentent 2 à 5% des cancers mammaires. Nous rapportons le cas de localisation mammaire chez une patiente de 50 ans. Il s'agit d'une tumeur classée T4d N1 M0. La tumeur est suspecte radiologiquement. Une microbiopsie est réalisée. L’étude anatomopathologique et immunohistochimique est en faveur d'une tumeur neuroendocrine primitive du sein à grande cellules exprimant les récepteurs progestéroniques seulement. Vu le caractère inflammatoire de la tumeur une chimiothérapie est démarrée avec bonne évolution clinique. A la fin de la chimiothérapie on prévoit de réaliser une mastectomie avec curage axillaire et en fonction des résultats définitifs, une radiothérapie. Une hormonothérapie sera envisagée une 2ème étude immunohistochimique sur la pièce de mastectomie. Vu la rareté des carcinomes neuroendocrines mammaires primitifs, il n'existe pas de standard thérapeutique et le pronostic demeure difficile à déterminer.

show abstract